98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/pbc.31999 | DOI Listing |
Cureus
August 2025
Department of Rheumatology, Faculty of Medicine and Pharmacy, Ibn ROCHD University Hospital, Casablanca, MAR.
Peliosis hepatis is a rare condition characterized by dilation of the hepatic sinusoids and the presence of multiple blood-filled cystic spaces within the liver parenchyma. It has been associated with a variety of etiologies, including infectious diseases, immunological disorders, malignancy, and certain medications. We report a case of a 24-year-old male who presented with polyarthritis lasting two months.
View Article and Find Full Text PDFPediatr Blood Cancer
August 2025
Health Management Center, Chongqing General Hospital, Chongqing, China.
Ugeskr Laeger
August 2025
Afdeling for Kræftbehandling, Københavns Universitetshospital - Rigshospitalet.
Peliosis hepatis is a rare benign vascular disorder characterized by dilatation of sinusoidal blood-filled spaces within the liver. Peliosis hepatis is most often idiopathic and asymptomatic, it can mimic malignancy and is difficult to diagnose. In this case report, a 41-year-old woman with breast cancer developed multiple hypodensities in the liver during chemotherapy.
View Article and Find Full Text PDFClin Liver Dis
August 2025
Department of Pathology, New York University Langone Health, 560 First Avenue, New York, NY 10016, USA.
Vascular liver pathology represents a heterogenous group of diseases impacted by the dual blood supply to the liver at each distinct microanatomic site. Portal vein-based disease is well described in association with portal vein thrombosis but may also precede or occur in the absence of thrombosis. Central vein-based disease is also well described in association with right heart failure and Budd Chiari syndrome but may show similar features with sinusoidal obstruction.
View Article and Find Full Text PDFJ Neuromuscul Dis
July 2025
Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands.
Background: Centronuclear myopathies represent a subset of debilitating genetic disorders, for which no treatment exists. The Unite-CNM trial (NCT04033159) aimed to assess the effect of an antisense oligonucleotide to reduce mRNA expression in X-linked myotubular myopathy (XLMTM) and autosomal dominant centronuclear myopathy (ADCNM).
Objective: The trial was discontinued due to tolerability concerns (hepatic and hematological).